SC75741

913822-46-5

C29H23N7O2S2

DMSO : >= 125 mg/mL (220.98 mM)

Apoptosis; Anti-infection; NF-kappaB

SC75741 is a broad and efficient NF-kappaB inhibitor with an IC₅₀ of 200 nM for p65^[1]. SC75741 blocks influenza viruses (IV) replication in non-toxic concentrations. SC75741 impairs DNA binding of the NF-kappaB subunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors. SC75741 subsequently inhibits caspase activation and blocks caspase-mediated nuclear export of viral ribonucleoproteins^[2]. IC50 & Target: 200 nM (NF-kappaB)^[1], caspase^[2] In Vitro: SC75741 (5 uM; 24-96 hours) inhibits long-term A549 cells proliferation^[2].
SC75741 (1-10 uM; 5.5-65 hours) reduces A549 cells viability in a concentration-dependent manner indicating a cytostatic effect for A549 cells within a time frame of about 50 and 65?hours^[2].
SC75741 (5 uM; 24 hours) strongly inhibits cleavage of the effector caspase 3 induced upon H7N7-infection^[2]. In Vivo: SC75741 (intraperitoneal injection; 15?mg/kg; for 2 days) leads to a reduced propagation of the H5N1 virus mRNA by 90% in the lungs of infected mice^[2].
The plasma-levels of SC74751 (intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; for 3.5 and 6 hours) after i.v. administration decreases mono-exponentially and half-life is roughly 40 min. After i.p. administration, elimination of SC75741 seems to be limited by a slow uptake from the peritoneum and a half-life of 55 min is observed^[1].